Generation of donor-specific immunotolerance in renal-allograft recipients

The kidney cannot be successfully grafted without immunosuppressive therapy. A unicenter retrospective study has evaluated the efficiency of immunosuppression with daclizumab (Zenapax) versus alemtuzumab (Campath).Subjects and methods. After renal allotransplantation, 64 patients, including 34 and 3...

Full description

Bibliographic Details
Main Authors: V. A. Goryainov, M. M. Kaabak, M. M. Morozova, L. A. Shishlo, N. N. Babenko, A. K. Zokoyev
Format: Article
Language:English
Published: N.V. Sklifosovsky Research Institute for Emergency Medicine of Moscow Healthcare Department 2018-08-01
Series:Трансплантология (Москва)
Subjects:
Online Access:https://www.jtransplantologiya.ru/jour/article/view/240
_version_ 1797696935790903296
author V. A. Goryainov
M. M. Kaabak
M. M. Morozova
L. A. Shishlo
N. N. Babenko
A. K. Zokoyev
author_facet V. A. Goryainov
M. M. Kaabak
M. M. Morozova
L. A. Shishlo
N. N. Babenko
A. K. Zokoyev
author_sort V. A. Goryainov
collection DOAJ
description The kidney cannot be successfully grafted without immunosuppressive therapy. A unicenter retrospective study has evaluated the efficiency of immunosuppression with daclizumab (Zenapax) versus alemtuzumab (Campath).Subjects and methods. After renal allotransplantation, 64 patients, including 34 and 30 patients, were treated with daclizumab and alemtuzumab, respectively. The absolute count of peripheral blood lymphocytes was measured. Renal grafts were morphologically assessed as described by Banff.Results. After administration of alemtuzumab, there was a more pronounced decrease in the absolute count of peripheral blood lymphocytes and the rate of acute rejection crisis was 1.5 times lower than that after use of daclizumab.Conclusion. During the study, alemtuzumab demonstrated a more marked immunosuppressive activity than did daclizumab and the ability of the former to generate donor-specific immunotolerance in renal-allograft recipients.
first_indexed 2024-03-12T03:33:13Z
format Article
id doaj.art-e45cac67a0e74be1a92826ba9496924f
institution Directory Open Access Journal
issn 2074-0506
2542-0909
language English
last_indexed 2024-03-12T03:33:13Z
publishDate 2018-08-01
publisher N.V. Sklifosovsky Research Institute for Emergency Medicine of Moscow Healthcare Department
record_format Article
series Трансплантология (Москва)
spelling doaj.art-e45cac67a0e74be1a92826ba9496924f2023-09-03T13:24:17ZengN.V. Sklifosovsky Research Institute for Emergency Medicine of Moscow Healthcare DepartmentТрансплантология (Москва)2074-05062542-09092018-08-0101464910.23873/2074-0506-2009-0-1-46-49229Generation of donor-specific immunotolerance in renal-allograft recipientsV. A. Goryainov0M. M. Kaabak1M. M. Morozova2L. A. Shishlo3N. N. Babenko4A. K. Zokoyev5ГУ РНЦХ им. акад. Б.В. Петровского РАМНГУ РНЦХ им. акад. Б.В. Петровского РАМНГУ РНЦХ им. акад. Б.В. Петровского РАМНГУ РНЦХ им. акад. Б.В. Петровского РАМНГУ РНЦХ им. акад. Б.В. Петровского РАМНГУ РНЦХ им. акад. Б.В. Петровского РАМНThe kidney cannot be successfully grafted without immunosuppressive therapy. A unicenter retrospective study has evaluated the efficiency of immunosuppression with daclizumab (Zenapax) versus alemtuzumab (Campath).Subjects and methods. After renal allotransplantation, 64 patients, including 34 and 30 patients, were treated with daclizumab and alemtuzumab, respectively. The absolute count of peripheral blood lymphocytes was measured. Renal grafts were morphologically assessed as described by Banff.Results. After administration of alemtuzumab, there was a more pronounced decrease in the absolute count of peripheral blood lymphocytes and the rate of acute rejection crisis was 1.5 times lower than that after use of daclizumab.Conclusion. During the study, alemtuzumab demonstrated a more marked immunosuppressive activity than did daclizumab and the ability of the former to generate donor-specific immunotolerance in renal-allograft recipients.https://www.jtransplantologiya.ru/jour/article/view/240(аллогенная) трансплантация почкииммунодепрессиясравнительное исследованиезенапакскэмпас
spellingShingle V. A. Goryainov
M. M. Kaabak
M. M. Morozova
L. A. Shishlo
N. N. Babenko
A. K. Zokoyev
Generation of donor-specific immunotolerance in renal-allograft recipients
Трансплантология (Москва)
(аллогенная) трансплантация почки
иммунодепрессия
сравнительное исследование
зенапакс
кэмпас
title Generation of donor-specific immunotolerance in renal-allograft recipients
title_full Generation of donor-specific immunotolerance in renal-allograft recipients
title_fullStr Generation of donor-specific immunotolerance in renal-allograft recipients
title_full_unstemmed Generation of donor-specific immunotolerance in renal-allograft recipients
title_short Generation of donor-specific immunotolerance in renal-allograft recipients
title_sort generation of donor specific immunotolerance in renal allograft recipients
topic (аллогенная) трансплантация почки
иммунодепрессия
сравнительное исследование
зенапакс
кэмпас
url https://www.jtransplantologiya.ru/jour/article/view/240
work_keys_str_mv AT vagoryainov generationofdonorspecificimmunotoleranceinrenalallograftrecipients
AT mmkaabak generationofdonorspecificimmunotoleranceinrenalallograftrecipients
AT mmmorozova generationofdonorspecificimmunotoleranceinrenalallograftrecipients
AT lashishlo generationofdonorspecificimmunotoleranceinrenalallograftrecipients
AT nnbabenko generationofdonorspecificimmunotoleranceinrenalallograftrecipients
AT akzokoyev generationofdonorspecificimmunotoleranceinrenalallograftrecipients